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Abstract 
Lyophilized muco-adhesive wafers with optimum drug loading for potential buccal delivery 
have been developed. A freeze-annealing cycle was used to obtain optimized wafers from 
aqueous gels containing 2% κ-carrageenan (CAR 911), 4% pluronic acid (F127), 4.4% w/w 
polyethylene glycol with 1.8% w/w paracetamol or 0.8% w/w ibuprofen. Thermogravimetric 
analysis showed acceptable water content between 0.9 – 1.5%. Differential scanning 
calorimetry and X-ray diffraction showed amorphous conversion for both drugs. Texture 
analysis showed ideal mechanical and mucoadhesion characteristics whilst both drugs 
remained stable over six months and drug dissolution at a salivary pH showed gradual release 
within two hours. The results show the potential of CAR 911 and F127 based wafers for 
buccal mucosa drug delivery.  
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1.0 Introduction 
 Mucosal drug delivery systems have many advantages such as bypassing first pass 
liver metabolism and avoiding GI enzymatic degradation. Drug absorption via the buccal 
mucosa surface and into the systemic circulation is relatively fast (compared to the skin) 
owing to the highly vascularized structure underneath the mucosal tissues [1, 2].  
 Lyophilisation has been used in pharmaceutical industries to improve the stability of 
formulations. The investigation of fundamental physical phenomena occurring during each 
step of freeze drying has enabled formulators to produce stable and well-designed freeze-
dried pharmaceutical dosage forms [3]. Freeze dried products do not necessarily need to be 
refrigerated and can be stored at ambient temperatures. This will be favourable for labile 
drugs including vaccines and proteins [4]. 
 Lyophilisation comprises a freezing step where ice crystals form and the solute 
becomes extremely concentrated. As the temperature falls below the glass transition 
temperature (Tg), the system is changed into a viscous glass. Incomplete crystallization may, 
however, lead to sample collapse or formation of mixtures of different polymorphic forms 
that causes problems in characterization and manufacturing reproducibility. Frozen products 
can be categorized as either crystalline or amorphous glass in structure. Crystalline products 
have a distinct “eutectic” freezing/melting point which is referred to as the collapse 
temperature. Amorphous products have a corresponding “glass transition” temperature and 
they are much more difficult to freeze-dry. Even though most materials that are freeze dried 
are actually amorphous, the term “eutectic” is often used to define the freezing/melting point 
of sample [4].  
 To optimise the process of solute crystallization during freezing, thermal treatment, or 
“annealing”, will be advantageous. Annealing is the process of heating a sample above its 
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glass transition temperature (but below the eutectic and/or ice melting temperature) and 
allowing the glass to relax and crystallize. Metastable glass formation is possible depending 
on the freezing rate and/or the excipients in the formulation which should be avoided as the 
metastable glass will eventually crystallize [4, 5]. Elevation of temperature above the Tg 
during annealing reduces the viscosity and increases mobility of the solute molecules and 
helps prevent crystallization. However, the temperature should remain below the 
eutectic/collapse temperature to avoid ice melting. The thermal treatment causes an increase 
in the size of both solute and ice crystals resulting in reduced product resistance, faster water 
vapour transport and shorter primary drying times [6]. 
 Lyophilized wafers can be prepared by freeze-drying aqueous gels of polymer(s) to 
form a porous polymeric inter-connecting network [7]. Swelling release systems formulated 
with hydrophilic polymers with several hydrogen bonding sites can be produced [8]. During 
drug dissolution, swelling and diffusion compete, with swelling dominating initially, by 
increasing the gel layer thickness and subsequently reaches a plateau due to synchronization 
of swelling, drug diffusion and dissolution [9] [10]. To obtain optimum bioavailability, 
swelling, mucoadhesion and dissolution characteristics must be optimized as they affect 
residence time and eventual drug release [11].  
 In the present study, the development and characterization of lyophilized wafers 
prepared by freeze-drying gels comprising the natural polysaccharide polymer κ-carrageenan 
(κ-CAR 911), pluronic acid (F127) and polyethylene glycol 600 (PEG 600), loaded with 
model soluble (paracetamol - PM) and insoluble (ibuprofen - IBU) drugs for buccal delivery 
purposes are reported.  
  
5 
 
2.0 Experimental  
2.1 Materials 
 Gelcarin [(κ-CAR 911, batch number: 50102070)] were gifts from BASF and 
obtained from the UK distributor Honeywill & Stein LTD (Surrey, UK). Pluronic acid [F127 
(batch number: 038k0071)], paracetamol [PM (batch number: RB16652)], polyethylene 
glycol [PEG 600 (batch number: 0001409391)] and ibuprofen [IBU (batch number: 
026H1368)] were purchased from Sigma-Aldrich (Gillingham, UK).   
 
2.2 Gel preparation 
 Different formulations were prepared based on varying concentrations of model drugs 
and plasticizer (PEG 600) as summarised in Table 1. Briefly, gels [12] were prepared by 
initially dissolving F127 in cold water (< 15°C) kept for two hours before addition of κ-CAR 
911 and PEG 600 to the resulting solution and left overnight at room temperature to ensure 
complete hydration of κ-CAR 911. The mixture was then heated with continuous stirring 
using an overhead stirrer at 40-50°C. The model drug (PM or IBU) was added and mixing 
continued for a further 5-10 min. Addition of PM to the system was straight forward, 
however, two different strategies were employed to incorporate the maximum amount of 
IBU. 
a. IBU (0.3-1.0% w/w) was added to the F127 solution at the same time as κ-CAR 911 and 
PEG 600 and left for 24 hours.  
b. IBU (0.3-1.0% w/w) was dissolved separately in 2 ml of ethanol and the resulting 
solution added to the final gel comprising κ-CAR 911, F127 and PEG 600.  
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2.3 Thermal annealing (DSC studies) of gels 
 DSC analysis of the gels was conducted with a Q2000 instrument (TA Instruments, 
Crawley, UK) under a dry nitrogen atmosphere. The instrument was calibrated with indium 
and sapphire prior to sample analysis. The experiment was performed by loading 3-10 mg of 
gel into T-zero aluminium pans (75 µL), hermetically sealed and cooled to -80°C to ensure 
complete freezing of all components before being heated from -80°C to 80°C at a rate of 
10°C/min.  
 
2.4 Freeze drying process 
 An AdVantage freeze dryer (SP scientific, Ipswich, UK) was employed in automatic 
mode. Preliminary investigations involved obtaining wafers using an annealing procedure 
[13] by programming the freezing and primary/ secondary drying cycles according to 
preliminary experiments. 10 g of the gel was poured into six well polystyrene plates (35.4 
mm diameter) to a height of 1 cm. Gels were gradually cooled from room temperature to 5°C, 
cooled to 0°C and maintained for 40 minutes, and cooled finally to -55°C and maintained for 
1 hour. Subsequently, annealing was performed by increasing the temperature to -35°C. The 
annealing process lasted 3 hours to provide sufficient time for large ice crystal formation. The 
temperature was returned to the initial temperature and maintained for 2 hours before primary 
drying was initiated. During primary drying, the temperature was increased from -55°C to -
10°C and eventually 0°C (5°C lower than the eutectic points) to prevent melt back and 
preserve the stability of all the components. The whole primary drying procedure was 8 hours 
at -10°C followed by 6 hours at -0°C. To increase the stability of the freeze-dried wafers at 
room temperature, secondary drying was performed for 2 hours to further reduce residual 
water content.  
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2.5 Thermal Analysis  
(i)   Thermogravimetric analysis (TGA) 
 TGA was used to determine the residual water in the wafers and the effect of 
concentration of model drugs on their water content. About 3-10 mg of sample was 
accurately weighed, placed in aluminium pans (100 µL) and weight loss measured using a 
high resolution TGA 2950 instrument (TA Instruments, Crawley- UK). The experimental 
program involved heating the samples from 25°C to 150°C at a heating rate of 10°C/min. 
Each experiment was performed three times.     
 
(ii)   Differential scanning calorimetry (DSC) 
 The thermal profiles of the optimized wafers containing IBU or PM were 
investigated. Samples were placed in T-zero pans, cooled down to -80°C, maintained at this 
temperature for 5 minutes before heating up to 180°C at a rate of 10°C/min and kept at this 
temperature for 3 minutes to allow complete melting. The run proceeded by cooling the 
sample at a rate of -10°C/min back to -80°C. This process was repeated twice to investigate 
the stability of the polymer matrix and model drugs during the heating cycle.  
 
2.6 X-Ray powder diffraction (XRPD) 
 XRPD was used to determine the physical form of the individual components present 
in the wafer (polymers and drugs). A D8 Advance XRPD diffractometer (Bruker, Coventry, 
UK) equipped with a Lyn X – Iris detector and 6.5 mm slit size was employed to obtain 
results in reflection and transmission modes. The instrument was set at 40 kV and 40 mA 
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with primary solar slit of 4° and a secondary solar slit of  2.5 mm while the scattered slit was 
0.6 mm. Samples were scanned at a speed of 0.02°, 2θ step size every 0.1 seconds.  
 
2.7 HPLC analysis 
 HPLC analysis was performed using an ODS C18 reverse phase (5μm particle size) 
column (Hichrom H50DS-3814), mobile phases of methanol: water: ortho-phosphoric acid 
(74:24:2), flow rate 1.50 ml/min for IBU and methanol: water: ortho-phosphoric acid 
(25:75:3 v/v %), flow rate 1mL/min for PM and diode array UV detection at 214 and 245nm 
for IBU and PM respectively. A 0.50 mg/ml standard solution of IBU was prepared, serially 
diluted (0.05, 0.075, 0.10, 0.125 and 0.15 mg/ml) used to plot a calibration curve. The 
calibration curve for PM was plotted by preparing 1mg/ml standard solution of PM and 
serially diluted to 0.10, 0.15, 0.20, 0.25, 0.30 mg/ml. 
 
2.8 Stability test  
 The formulations wrapped in paraffin film (to prevent moisture absorption by κ-CAR 
911, which is hygroscopic) were stored at room temperature and 45% relative humidity (RH) 
over a six month period and the drug content assayed monthly using HPLC. Drug stability 
over the storage period was analysed by dissolving wafers in deionized water prior to 
analysing on the HPLC. Samples were analysed at the following time points: day 1 (freshly 
prepared), 7 days, and then at 2, 4 and 6 months. Pure crystalline IBU and PM powders 
stored under similar conditions as the wafers were used as controls.   
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2.9 Scanning electron microscopy (SEM) 
 SEM was used to evaluate the topographic characteristics and morphology of the 
wafers. The analyses were carried out using a Jeol Instrument (Japan) with back scattered 
electrons and artificial shadowing ability with uncoated samples at low vacuum (< 20 Pa) and 
an accelerating voltage of 20 kV.  
 
2.10 Texture analysis 
(i) Mechanical characteristics  
 This was used to select optimized wafers with acceptable flexibility (PEG 600 
concentration) for drug loading as well as to determine the effect of increasing drug content. 
The instrument employed was a “Texture analyser HD-plus” with Exponent software to plot 
and display the data. Before compression, the thickness of the wafers containing 4.4-5.5% 
w/w PEG 600 was measured by a micro screw-gauge (four edges and one in the middle). The 
average thickness (ranging from 3.5-3.7 mm) of each specific sample was entered into the 
texture analyser software prior to compression. The texture analyser was set to compression 
mode and a force was applied by a P6 (6 mm diameter) cylindrical stainless steel probe at a 
speed of 0.1 mm/sec to compress the wafer to the depth of 2 mm, held for 2 sec before 
returning to the starting position at a speed of 1 mm/sec. The peak compression force (CF) 
representing resistance to compression and work of compression (WOC) of the wafers 
containing different concentrations of PEG 600 and model drugs were measured. 
 
(ii)  In vitro mucoadhesivity studies 
 Mucoadhesivity experiments were conducted by employing a 75 mm diameter 
stainless steel probe attached to the Texture analyser-HD Plus instrument. The lyophilised 
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wafer’s specimen was cut to 3 cm×3 cm size and attached to the probe using double sided 
adhesive tape. A Petri dish containing set agar gel, equilibrated with 200µL buffer solution 
(pH=6.2) was used as the mucosal substrate to simulate the buccal mucosa. The sample was 
placed in contact with the agar surface, maintained for one minute to allow hydration and 
maximum contact between the sample and the mucosal substrate. The Texture Analyser was 
programmed to work in tension mode and the probe detached at a pre-test speed of 0.5 
mm/sec, and test speed of 1mm/sec. The maximum force applied to separate the specimen 
from the agar surface and work of adhesion (WOA), were determined.     
 
2.11 Hydration (swelling) studies  
 These studies investigated the maximum time required for the wafers to completely 
hydrate and their maximum swelling capacity in phosphate buffer solution. The buffer was 
prepared by the addition of 100 ml of KH2SO4 (0.1M) to 13 ml of NaOH (0.1M). Since the 
secretion of saliva is 0.3 ml/min [14], the volume of the medium was 42 ml and wafers were 
immersed for 140 minutes. Wafers were cut to 3 cm×3 cm square strips, weighed and placed 
in the buffer solution (pH= 6.2). The weight changes in the sample were measured every 20 
minutes till constant weight up to a maximum of 140 minutes and the data plotted as weight 
change versus time. Calculation of % swelling (% weight change) was determined using 
equation 1 where W0 and Wt are the weights of the lyophilized wafer initially and at time t 
respectively. Each data point represents the mean (± s.d.), of three replicates. 
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2.12 Drug dissolution studies 
 Drug dissolution studies were performed at 37°C using 42 ml buffer solution (as in 
swelling studies) with pH=6.2 simulating that of saliva. Dissolution media was sampled at 
intervals of 2 minutes from time zero and drug measured using the HPLC method above. 
Drug released (mg) were calculated from the calibration curves and cumulative percentage 
release versus time profiles plotted. The kinetics of PM and IBU release from the wafer was 
assessed by fitting the dissolution data (percentage cumulative release against time) to the 
Higuchi, Hixon-Crowell, Korsmeyer–Peppas, first or zero order equations in order to 
determine the drug release mechanism.  
 
2.13 Statistical analysis  
To compare the dissolution and mucoadhesion results statistical analyses were employed by 
one-way ANOVA. The results were considered statistically significant if a p value of < 0.05 
was obtained. All measurements were performed in triplicate and the results are presented as 
the mean ± standard deviation (s.d).  
 
3.0 Results and discussion 
3.1 Preliminary development 
 Establishing a suitable thermal profile for any gel prior to freeze-drying was critical in 
developing an optimized lyophilization cycle. Because of possible changes to wafer 
properties due to addition of the model drug or changes in plasticizer concentration, 
complimentary DSC data was required to detect the critical points. The eutectic point Tc (Teu) 
was observed at 7.91°C and 10.91°C for IBU and PM loaded wafers respectively. To ensure 
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that the formulation did not collapse from melt back and/or incomplete ice removal  the 
product temperature was maintained below the Tc/Teu (collapse/eutectic temperature) to retain 
interstitial space in the solid phase and make it capable of supporting its own weight after the 
ice removal and subsequently preserve the wafer’s structure [15, 16]. 
   
Visual evaluation of wafers  
 Evaluation of the wafers formulated with 2% κ-CAR 911, 4% F127 and varying 
concentrations of PEG 600 with the freeze annealing process were conducted and optimum 
wafers were selected based on the following criteria: 
 Softness: wafers must be soft and easy to apply on the mucosal tissues.   
 Plasticity: the wafer should not be brittle and fragile as it will affect physical and 
mechanical stability during handling as well as potential contact irritation during 
application.  
 Thickness: Ideal wafer must have optimum thickness (less than 1cm pre-hydration) to 
ensure convenience for patients when applied to the buccal mucosa area. Thick wafers 
present the possibility of accidental chewing and dislodging by tongue movement. In 
addition, thickness of the wafer affects the drug release rate since it determines the 
diffusion distance through the initial gel formed following hydration.  
 
Based on visual evaluations gels comprising 2% w/w κ-CAR 911, 4% w/w F127 and 
4.4% w/w PEG 600 with maximum drug loading of 1.8% w/w PM or 0.8% w/w IBU 
was selected as optimum for freeze-drying. 
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3.2 Thermal analysis studies 
(i) Thermogravimetric analysis (TGA) 
 The residual water determined immediately after freeze-drying for wafers prepared 
from the following gel formulations (2% κ-CAR 911 + 4% F127 + 4.4 % PEG 600; 2% κ-CAR 
911 +  4% F127 + 4.4 % PEG 600 + 0.8% IBU and 2% κ-CAR 911 +  4% F127 + 4.4 % PEG 600 + 
1.8% PM) were respectively 1.5 (± 0.1), 1.1 (± 0.2) and 0.9 (± 0.01). Following freeze-drying, the 
water content should be at a minimum level, typically between 0.5% and 3% [18]. This is 
because there is a potential for high residual water to act as seeds to initiate and accelerate the 
crystallization of amorphous drug during storage. Water is also a very effective plasticizer 
which significantly depresses the Tg of the amorphous drug and excipients by increasing 
molecular mobility which can result in instability [19]. The results confirmed that annealing 
is a desirable process to develop wafers with appropriate stability due to lower residual water 
content [13].  
 The water content of drug (IBU and PM) loaded wafers showed that addition of 
model drugs resulted in a reduction of residual water in the wafer. This can be attributed to 
the competition of the drug with water molecules for interaction with κ-CAR 911. 
Interestingly, the results showed that the amount of residual water was reduced considerably 
due to addition of PM compared with IBU loaded wafers .Wu and McGinity [20] have shown 
that Tg of polymers would be decreased due to the presence of IBU within the polymeric 
wafer.        
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(ii) Differential scanning calorimetry (DSC) 
 The DSC results for the blank and drug loaded wafers demonstrated that both model 
drugs were present in amorphous form. Figure 1a&b represent DSC thermograms of pure 
IBU which showed that during the first heating cycle a sharp melting transition was detected 
at 77.68°C and following the rapid cooling, glass transition of the amorphous form was 
detected at - 45.08ºC though this transition was shifted to - 59.08°C within the wafer. Figure 
1c also showed three sharp peaks (- 1.78°C, 38.6°C and 26.46°C) corresponding to PEG 600, 
F127 and the mixture of these two polymers [21] respectively and the disappearance of the 
IBU melting transition. 
 Similarly, pure PM (Figure 1d&e) showed a sharp melting peak at 169.76ºC in the 
first heating cycle. During the rapid cooling, the crystalline drug was changed to amorphous 
form. However, the amorphous form is unstable and recrystallized at 80.53ºC. The Tg of PM 
was detected at 24.11ºC and a sharp melting peak confirmed the recrystallization process. 
This result was compared with thermogram of the PM loaded wafer (Figure 1f) and showed a 
stable amorphous form of PM in the wafer with glass transition at 21.77ºC with the absence 
of the expected melt peaks 158.15ºC (orthorhombic polymorph) and 169.76ºC (monoclinic), 
confirming the existence of amorphous form of the drug in the wafer.  
 An interesting finding was the absence of the melting transition of the mixture of PEG 
600/F127 in PM loaded wafers possibly due to less water content compared with IBU loaded 
wafer. As noted above, the PM molecules compete with water molecules for interaction with 
binding sites on κ-CAR 911 through hydrogen bonds. This is possible given the higher 
amounts of PM within the polymeric matrix compared with IBU loaded wafers where the 
lower water content limited the interaction of PEG 600 and F127 as the presence of water in 
the system has a significant effect on interaction between PEG 600 and F127 [21].  
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3.3 X-ray powder diffraction (XRPD) 
 Figures 2a&b show the XRPD patterns for wafers containing IBU and PM. The X-ray 
patterns shown in Figure 2a correspond to the wafer containing all components (κ-CAR 911, 
F127, PEG 600 and IBU) which represents all the crystalline molecules present within the 
wafer’s matrix. The results demonstrate the absence of the main peak of crystalline IBU that 
should have appeared at 16.2 (2θ) according to the XRPD library data base. Similar results 
were observed for PM loaded wafer (Figure 2b), as evidenced by the absence of the main 
crystalline peak expected at about 24.5 (2θ) for PM. This confirmed the DSC results and 
showed that the crystalline IBU or PM originally added to the system was transformed into 
amorphous form during freeze-drying to produce the wafers.  
 
3.4 Stability test   
 HPLC assay showed that the amount of drug within the wafers during six months 
storage at room temperature and 45 ± 5% RH remained fairly constant. For IBU wafers, the 
percent drug content varied from 99.86% at time zero to 99.28% after six months of storage 
whilst for PM loaded wafers, the percent drug content varied from 99.90% at time zero to 
99.15% after six months. These results show the ability of κ-CAR 911, F127 and PEG 600 
based wafers to maintain the chemical stability of IBU and PM. However, this was over six 
months storage and the stability profiles over a longer storage period corresponding to the 
expected shelf time as well as under accelerated conditions will need to be investigated.  
 
3.5 Scanning electron microscopy (SEM) 
 SEM was employed to assess the surface characteristics (morphology) of the 
lyophilized wafers and determine its relation to swelling, dissolution and mucoadhesion 
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characteristics. The SEM images of different formulations are shown in Figure 3a-3d with 
different degrees of porosity. The SEM images of drug loaded wafers showed significant 
differences in surface topography of wafers formulated with the two model drugs. The PM 
loaded wafer at high drug loading (1.8 % w/w) showed the least porosity as the surface 
texture appeared to be leafy while the IBU loaded wafer showed a more porous texture with 
uniform pore size distribution. The leafy surface structure and reduced porosity could be 
attributed to the higher amounts of PM incorporated in the wafer’s matrix. However, the 
wafers containing lower amounts (0.8 % w/w) of PM (Figure 3d) showed a more porous 
structure. Wafers with larger pores allow a more rapid ingress of water during dissolution 
which is expected to increase drug release rates.  
 
3.6 Texture analysis 
(i) Mechanical characteristics 
 Figure 4a shows that addition of IBU increased the work of compression (WOC) [17] 
while PM decreased it to approximately half that of IBU loaded wafers, and also lower than 
the blank (non drug loaded wafer). These results combined with SEM observations showed 
that addition of PM decreased mechanical strength due possibly to the reduced availability of 
free polymer as a result of the higher amounts of PM distributed throughout the matrix.  
 To evaluate the effect of PEG 600 concentration, a new set of experiments were 
conducted. Optimised wafers prepared from gels containing 2% κ-CAR 911, 4% F127 and 
1.8 % PM with varying PEG 600 concentrations (4.4, 5.0 and 5.5%) showed WOC (Nmm) 
values of 3.4 (± 0.3), 3.5 (± 0.5) and 2.9 ± 0.2 respectively. The peak compression force 
values (N) were also respectively 4.5 (± 0.2), 3.4 (± 0.3) and 3.1 (± 0.2). The results showed 
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that increasing the levels of PEG 600 beyond 4.4 % w/w did show further increase in WOC, 
therefore PEG 600 at 4.4% w/w within the gel for both blank and drug loaded wafers was the 
concentration of choice.  
 
(ii)  In vitro mucoadhesion        
During the mucoadhesivity studies three parameters were measured; (i) WOA (work required 
to overcome the attractive forces between the surface of the wafer and the agar), (ii) 
stickiness factor (maximum force required for detaching the wafer from the surface of the 
agar) and (iii) cohesiveness (the distance the wafer travels in mm to detach from the agar 
surface). All of these factors are correlated with the strength of the bonds formed between the 
polymeric matrix and agar during the contact time [30].     
 Figure 4b shows the WOA and stickiness for the various formulations. Both of the 
above parameters were significantly affected by PEG 600. The results showed that maximum 
mucoadhesivity was observed for the wafer comprising 2% w/w of κ-CAR 911 and 4% w/w 
F127 in the presence of 4.4% PEG 600 which previously showed appropriate flexibility and 
remained stable during handling. Shaikh and co workers [26] reported that the presence of 
PEG 600 increased the quantity of residual water that resulted in drug precipitation and a 
slight decrease in the adhesive performance. Therefore, the amount of the PEG 600 in the 
system should be kept at the lowest optimum level. Further, incorporating the hydrophobic 
drug (IBU) in the wafers’ matrix resulted in a slight decrease in mucoadhesion compared 
with blank wafer though the difference was not significant (p=0.0532). Interestingly, addition 
of PM which is a hydrophilic drug resulted in an increase in the WOA, stickiness and 
cohesiveness. 
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 κ-CAR 911 exhibit bioadhesive characteristics effect due to its anionic nature and 
numerous hydrogen bonding groups which allow it to bind to mucosal tissues more 
efficiently. Scientifically, ionisable polymers existing in their unionized form are able to form 
non-covalent bonds with mucus glycoprotein [27]. Based on the chemical structure of mucin, 
there is the feasibility of hydrogen bond formation between mucin and κ-CAR 911 as well as 
formation of ionic bonds between the sulphate group in κ-CAR 911 and NH2 group in mucin 
which could result in a stronger mucoadhesion force. Ruiz and Ghaly [28] have previously 
reported the ability of CAR based tablets to adhere to agar gel surface. In addition to 
hydrogen bonds, mucoadhesion can be generated due to van der Waals and dative bonds or 
entanglement between polymeric matrix and agar [29]. 
 
3.7 Swelling studies  
 Figure 5a shows the swelling profiles of optimised wafers formulated with 2% w/w 
CAR 911, 4% w/w F127 and 4.4% w/w PEG 600 containing either IBU or PM. The results 
showed that the maximum swelling capacity for wafers in buffer solution occurred within 40 
minutes. In particular, the blank and IBU loaded wafers hydrated relatively more rapidly. The 
drug loaded formulations attained maximum swelling of 720% and 500% for IBU and PM 
loaded wafers respectively within 20 minutes after which the weight changes remained 
constant. The hydration and swelling capacity for IBU loaded wafer in the buffer solution 
was higher than blank and PM loaded wafer. This phenomenon can be related to the more 
extensive porosity in IBU wafer and acidic nature of IBU compared to PM molecules which 
interacted more readily with κ-CAR 911 through hydrogen bond formation. These differences 
impact on mucoadhesion and expected to affect drug release rates. 
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3.8 Drug dissolution studies 
 Figure 5b compares the dissolution profiles for IBU and PM within the wafers in 
buffer solution. PM is a weak basic drug with pKa 9.5 and is stable in alkali condition whilst 
IBU is a relatively weak acidic with the pKa about 4.4 and low solubility in water or at acid 
pH. IBU was released from the wafer’s matrix more slowly initially however; it showed 
faster release profiles reaching about 30% in 20 minutes and ultimately 75% after 120 
minutes. In contrast, PM was initially released from wafer’s matrix relatively fast and 
reached a plateau (about 40%) within 10 min. The maximum % drug release from the PM 
loaded wafer reached 50% after 120 minutes, which was considerably lower compared with 
IBU loaded wafer. These differences can be explained by the swelling studies as the swelling 
capacity of IBU loaded wafers was significantly higher than the PM loaded wafers. The 
release profiles for both IBU and PM from the wafers were generally similar and seems to 
confirm the observation that IBU and PM were both present in the wafers in the amorphous 
form [31]. Conventionally, the amorphous form of a drug possessing higher water solubility 
is expected to have higher rates of dissolution and therefore may account for the higher than 
expected rates of release by diffusion and eventual erosion of the polymer matrix when 
compared with the  crystalline drug.  
 The R
2
 values show that the kinetic model that best fit the release data for both drugs 
consistently was the Korsmeyer-Peppas (equation 2) which involved a combination of 
diffusion in the first step followed by erosion of the polymeric matrix.  
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 Where Qt is the amount of drug released in time t, Q∞ is the initial amount of drug 
present in the film, k is a constant comprising the structural and geometric characteristics of 
the formulation and n is the release exponent [22, 23]. As shown in Table 2, the R
2
 values 
determined were 0.99 and 0.96 for IBU and PM wafers respectively. Since, IBU loaded 
wafers showed 0.45 > n > 0.89, the drug release from the polymeric matrix was based on 
anomalous transport which means that diffusion and erosion played the key role in drug 
release behaviour [24]. The n value for PM loaded wafers however, showed the value of n ≤ 
0.45 corresponding to case І diffusional (Table 2) due to diffusion through the pores of the 
matrix when the polymer chains relax and is known as diffusion-controlled release systems 
[25].  
4.0 Conclusion  
 The development and optimisation of buccal wafers has been achieved by freeze-
drying gels combining two polymers 2% w/w κ-CAR 911 and 4% w/w F127 incorporating 
4.4 % w/w PEG 600 as well as 0.8% w/w or 1.8% w/w IBU and PM loaded wafers. The 
results also showed the conversion of crystalline drugs to the amorphous form during gel 
formation and freeze-drying and the wafer’s matrix demonstrated the ability to maintain the 
two model drugs in a stable amorphous form during storage over a six month period. The 
wafers showed ideal release patterns in conditions simulating those of saliva and coupled 
with the desirable mucoadhesive characteristics, have potential for buccal drug delivery.  
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Figure 1  DSC thermograms showing (a) melting point of pure IBU (b) Tg of pure IBU after 
rapid cooling from the melt (c) wafer produced from gels containing  2% w/w κ-CAR 911+ 
4% w/w F127+ 4.4% w/w PEG 600 +0.8% w/w IBU (d) melting point of pure PM (e) Tg of 
pure PM after rapid cooling from melt (f) wafer produced from gels containing 2% w/w κ-
CAR 911+ 4% w/w F127 + 4.4% w/w PEG 600 + 1.8% w/w PM. 
 
Figure 2 XRPD diffractograms showing the crystallographic patterns of (a) wafer containing 
IBU (b) wafer containing PM. (Both demonstrate the absence of the peak belonging to the 
crystalline forms of the two model drugs and confirm the existence of amorphous PM and 
IBU within the wafers).  
 
Figure 3 SEM images showing the surface morphology of (a) blank wafer (b) PM loaded 
wafer from gel containing 1.8% of the drug (c) IBU loaded wafer from gel containing 0.8% 
of drug and (d) PM loaded wafer from gel containing 0.8% of the drug.  
 
Figure 4 (a) Work of compression (Nmm) profiles for blank or drug loaded wafers produced 
from gels comprising 2% w/w κ-CAR 911+ 4% w/w F127 + 4.4% w/w PEG 600 or loaded 
with 0.8% IBU or 1.8% PM; (b) Mucoadhesion profiles showing work of adhesion (WOA), 
stickiness and cohesiveness of blank and drug (IBU or PM) loaded wafers. 
 
Figure 5 (a) Hydration profile showing the % swelling for the blank and drug laded wafers 
(IBU or PM) in phosphate buffer {mean ± s.d. n=3}; (b) Drug dissolution plots showing the 
release profiles of drugs form the wafers loaded with IBU and PM.  
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Table 1 Composition of the gels prepared during formulation development and optimization 
process for wafers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
κ-CAR 911  
(% w/w) 
F127  
(% w/w) 
PEG 600  
(% w/w) 
Drugs  
(% w/w) 
2.0 4.0 4.4 0.8 IBU 
2.0 4.0 5.0 0.8 IBU 
2.0 4.0 5.5 0.8 IBU 
2.0 4.0 4.4          1.8 PM 
2.0 4.0 5.0 1.8 PM 
2.0 4.0 5.5 1.8 PM 
2.0 4.0 4.4  0.9 IBU 
2.0 4.0 4.4 1.9 PM 
2.0 4.0 4.4 0.8 PM 
2.0 4.0 4.4   0.6 IBU 
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Table 2 Fitting of dissolution data for the two model drugs to various kinetic models to 
determine the mechanism of drug release from the wafers.  
Dissolution  models IBU wafer PM wafer 
Zero order k0 (%hr
-1
) 
R
2
 
RSM 
0.95 
0.95 
159.21 
1.25 
0.88 
101.59 
First order k1 (h
-1
) 
R
2
 
RSM 
1.3×10
-2
 
0.99 
4.04 
8.4 10
-3
 
0.90 
409.78 
Higuchi kH (% hr
-1/2
) 
R
2
 
RSM 
6.72 
0.97 
40.05 
5.40 
0.00 
212.00 
Hixson-Crowell  kHC (%h
-1/3
) 
R
2
 
RSM 
3.7 ×10
-3
 
0.99 
9.88 
2.5×10
-3
 
0.80 
444.49 
Korsmeyer-Peppas kP (hr
-n
) 
R
2
 
n 
RSM 
3.13 
0.99 
0.68 
14.17 
31.59 
0.96 
0.06 
7.63 
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Figure 4 
To be reproduced in colour on the Web (free of charge) and in black-and-white in print 
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Figure 5 
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